Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer

Yang,Tian; Chen,Mingwei; Chen,Tianjun; Thakur,Asmitananda

doi:10.3892/ol.2015.3531

Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer

Authors:
- Tian Yang
- Mingwei Chen
- Tianjun Chen
- Asmitananda Thakur
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: July 24, 2015 https://doi.org/10.3892/ol.2015.3531
Pages: 2584-2590

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Copper transporter family proteins may regulate the chemoresistance of non-small cell lung cancer (NSCLC) to platinum‑based anticancer drugs. The present study aimed to investigate the expression of these proteins in lung cancer tissue specimens for association with clinicopathological data and patient responses to chemotherapy and survival. A total of 54 patients with surgically resected NSCLC that received first‑line platinum‑based doublet chemotherapy were recruited in the present study, and the paraffin‑embedded pre‑treatment tumor tissue specimens were subjected to immunohistochemical analysis for the expression of human copper transporter 1 (hCtr1) and copper‑transporting p‑type adenosine triphosphatase 1 (ATP7A) and 2 (ATP7B). This cohort of patients with NSCLC received platinum‑based chemotherapy subsequent to the surgical removal of tumor lesions. ATP7B expression was found to be significantly associated with tumor cell differentiation, while hCtr1 expression was significantly associated with improved chemotherapeutic responses. The median survival time was 20 months in patients possessing tumors with high ATP7A expression, but >66 months in patients possessing tumors with low ATP7A expression at the end of the follow‑up (P<0.001). The median survival time at the end of the follow‑up was 15 months in patients with low tumor hCtr1 expression, but >66 months in patients with high tumor hCtr1 expression (P<0.001). High hCtr1 and low ATP7A expression were each favorable prognostic factors subsequent to chemotherapy for patients with resected NSCLC. Multivariate analysis revealed that high hCtr1 expression combined with low ATP7A expression, good tumor differentiation and female gender were all favorable independent predictive and prognostic factors for patients with resected NSCLC following chemotherapy. High hCtr1 expression combined with low ATP7A expression was associated with an improved prognosis in patients with resected NSCLC that received platinum‑based chemotherapy. Surgery combined with neoadjuvant chemotherapy may improve the survival time of patients with NSCLC.

View Figures

View References

1	Hildebrandt MA, Gu J and Wu X: Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 5:745–755. 2009. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA, Niland JC, et al: First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc Netw. 10:847–856. 2012.PubMed/NCBI
4	Ivy KD and Kaplan JH: A re-evaluation of the role of hcTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol. 83:1237–1246. 2013. View Article : Google Scholar : PubMed/NCBI
5	Choi MK and Kim DD: Platinum transporters and drug resistance. Arch Pharm Res. 29:1067–1073. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fisher MD and D'Orazio A: Phase II and III trials: Comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer. 2:21–22. 2000. View Article : Google Scholar : PubMed/NCBI
7	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
8	Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The tax 326 study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
9	Liu JJ, Lu J and McKeage MJ: Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr Cancer Drug Targets. 12:962–986. 2012. View Article : Google Scholar : PubMed/NCBI
10	Mellor HR and Callaghan R: Resistance to chemotherapy in cancer: A complex and integrated cellular response. Pharmacology. 81:275–300. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zisowsky J, Koegel S, Leyers S, et al: Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol. 73:298–307. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gupta A and Lutsenko S: Human copper transporters: Mechanism, role in human diseases and therapeutic potential. Future Med Chem. 1:1125–1142. 2009. View Article : Google Scholar : PubMed/NCBI
13	Kuo MT, Chen HH, Song IS, Savaraj N and Ishikawa T: The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 26:71–83. 2007. View Article : Google Scholar : PubMed/NCBI
14	Steiger D, Fetchko M, Vardanyan A, Atanesyan L, Steiner K, Turski ML, Thiele DJ, Georgiev O and Schaffner W: The drosophila copper transporter ctr1C functions in male fertility. J Biol Chem. 285:17089–17097. 2010. View Article : Google Scholar : PubMed/NCBI
15	Liang ZD, Long Y, Tsai WB, et al: Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther. 11:2483–2494. 2012. View Article : Google Scholar : PubMed/NCBI
16	Chen HH, Yan JJ, Chen WC, et al: Predictive and prognostic value of human copper transporter 1 (hctr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer. 75:228–234. 2012. View Article : Google Scholar : PubMed/NCBI
17	Taylor PT and Haverstick D: Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 97:1512005. View Article : Google Scholar : PubMed/NCBI
18	Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P and Howell SB: Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem. 54:1041–1049. 2006. View Article : Google Scholar : PubMed/NCBI
19	Nakagawa T, Inoue Y, Kodama H, Yamazaki H, Kawai K, Suemizu H, Masuda R, Iwazaki M, Yamada S, Ueyama Y, et al: Expression of copper-transporting p-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep. 20:265–270. 2008.PubMed/NCBI
20	Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH and Stravopodis DJ: Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol. 5:401–416. 2009.
21	Köberle B, Tomicic MT, Usanova S and Kaina B: Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
22	Abada P and Howell SB: Regulation of cisplatin cytotoxicity by cu influx transporters. Metal Based Drugs. 2010:3175812010. View Article : Google Scholar : PubMed/NCBI
23	Lenartowicz M and Krzeptowski W: Structure and function of ATP7A and ATP7B proteins-Cu-transporting ATPases. Postepy Biochem. 56:317–327. 2010.PubMed/NCBI
24	Zhou B and Gitschier J: Hctr1: A human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA. 94:7481–7486. 1997. View Article : Google Scholar : PubMed/NCBI
25	Cox DW and Moore SD: Copper transporting p-type atpases and human disease. J Bioenerg Biomembr. 34:333–338. 2002. View Article : Google Scholar : PubMed/NCBI
26	Howell SB, Safaei R, Larson CA and Sailor MJ: Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 77:887–894. 2010. View Article : Google Scholar : PubMed/NCBI
27	Zhang Y, Li M, Yao Q and Chen C: Roles and mechanisms of copper transporting atpases in cancer pathogenesis. Med Sci Monit. 15:RA1–RA5. 2009.PubMed/NCBI
28	Furukawa T, Komatsu M, Ikeda R, Tsujikawa K and Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 15:3268–3278. 2008. View Article : Google Scholar : PubMed/NCBI
29	Li ZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ, Wang F, Wang ZQ, Zhang DS, Li YH and Xu RH: Copper-transporting p-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). J Transl Med. 10:212012. View Article : Google Scholar : PubMed/NCBI
30	Inoue Y, Matsumoto H, Yamada S, Kawai K, Suemizu H, Gika M, Takanami I, Iwazaki M and Nakamura M: Association of ATP7A expression and in vitro sensitivity to cisplatin in non-small cell lung cancer. Oncol Lett. 1:837–840. 2010. View Article : Google Scholar : PubMed/NCBI
31	Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, ArmaizPena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, et al: Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res. 15:3770–3780. 2009. View Article : Google Scholar : PubMed/NCBI
32	Nakayama K, Kanzaki A, Terada K, Mutoh M, Ogawa K, Sugiyama T, Takenoshita S, Itoh K, Yaegashi N, Miyazaki K, et al: Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res. 10:2804–2811. 2004. View Article : Google Scholar : PubMed/NCBI
33	Yoshida H, Teramae M, Yamauchi M, Fukuda T, Yasui T, Sumi T, Honda K and Ishiko O: Association of copper transporter expression with platinum resistance in epithelial ovarian cancer. Anticancer Res. 33:1409–1414. 2013.PubMed/NCBI
34	Ishida S, McCormick F, SmithMcCune K and Hanahan D: Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 17:574–583. 2010. View Article : Google Scholar : PubMed/NCBI
35	Ogane N, Yasuda M, Kameda Y, Yokose T, Kato H, Itoh A, Nishino S, Hashimoto Y and Kamoshida S: Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin. Biomed Res. 34:143–151. 2013. View Article : Google Scholar : PubMed/NCBI